nach oben

Clinical Rheumatology

Erschienen in:

29.05.2020 | COVID-19 | Review Article Zur Zeit gratis

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments

verfasst von: Dieu-Donné Ouédraogo, Wendlassida Joelle Stéphanie Tiendrébéogo, Fulgence Kaboré, Honoré Ntsiba

Erschienen in: Clinical Rheumatology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Since December 2019, the pandemic caused by coronavirus disease 2019 (COVID-19) raises a real public health problem. COVID-19 appeared in Wuhan (Hubei province) in China. Drugs that have been used in rheumatology for decades seem to be effective in this infection and are for the most part being studied. The rational use of these anti-rheumatic drugs is based on the cytokinic storm (hyperproduction of IL1, IL6, TNF α) in the body by COVID-19 in its severe form. In this review, the authors make the difference between the infectious and auto-inflammatory part of COVID-19; the disease does not seem to be a risk factor for admission to the intensive care unit for patients suffering from inflammatory rheumatism; however, the poverty of studies on this subject should be noted. The authors also review anti-rheumatic drugs while studying COVID-19 treatment.

Organisation Mondiale de la Santé (OMS): www.euro.who.int/fr/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic. Accessed 13 May 2020

Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224):565–574. https://doi.org/10.1016/S0140-6736(20)30251-8 CrossRefPubMedPubMedCentral

Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 CrossRefPubMedPubMedCentral

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E et al (2020) Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19). Electronic address: https://www.lancovid.org. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis:101623. https://doi.org/10.1016/j.tmaid.2020.101623

Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, Ko WC, Hsueh PR (2020) Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. https://doi.org/10.1016/j.jmii.2020.02.012

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3 CrossRefPubMedPubMedCentral

Sarzi-Puttini P, Giorgi V, Sirotti S et al (2020) COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 38(2):337–342PubMed

Pires da Rosa G, Ferreira E (2020) Therapies used in rheumatology with relevance to coronavirus disease 2019. Clin Exp Rheumatol 38(2):370PubMed

Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ (2020) A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol 92:556–563. https://doi.org/10.1002/jmv.25729 CrossRefPubMedPubMedCentral

10.

Khalili JS, Zhu H, Mak A, Yan Y, Zhu Y (2020) Novel coronavirus treatment with ribavirin: groundwork for evaluation concerning COVID-19. J Med Virol. https://doi.org/10.1002/jmv.25798

11.

Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, Wang D, Liu C, Meng Y, Cui L, Yu J, Cao H, Li L (2020) Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. https://doi.org/10.1111/joim.13063

12.

Bhatnagar T, Murhekar MV, Soneja M, Gupta N, Giri S, Wig N, Gangakhedkar R (2020) Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res. https://doi.org/10.4103/ijmr.IJMR_502_20

13.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787–1799. https://doi.org/10.1056/NEJMoa2001282 CrossRefPubMed

14.

Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, Wang J, Qin Y, Zhang X, Yan X, Zeng X, Zhang S (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol 214:108393. https://doi.org/10.1016/j.clim.2020.108393 CrossRefPubMedPubMedCentral

15.

Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, Mosca M, Bombardieri S (2020) COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 38(2):175–180PubMed

16.

Cron RQ, Chatham WW (2020) The rheumatologist's role in Covid-19. J Rheumatol. https://doi.org/10.3899/jrheum.200334

17.

Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa248

18.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J (2020) Coronavirus infections and immune responses. J Med Virol 92(4):424–432. https://doi.org/10.1002/jmv.25685 CrossRefPubMedPubMedCentral

19.

Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—an update on the status. Mil Med Res 7(1):11. https://doi.org/10.1186/s40779-020-00240-0 CrossRefPubMedPubMedCentral

20.

Wu D, Yang XO (2020) TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. https://doi.org/10.1016/j.jmii.2020.03.005

21.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. https://doi.org/10.1016/j.cell.2020.02.052

22.

Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W (2020) Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. Biorxiv 2020(1):26.919985. https://doi.org/10.1101/2020.01.26.919985 CrossRef

23.

Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, Ju X, Liang Z, Liu Q, Zhao Y, Guo F, Bai T, Han Z, Zhu J, Zhou H, Huang F, Li C, Lu H, Li N, Li D, Jin N, Penninger JM, Jiang C (2014) Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 5:3594. https://doi.org/10.1038/ncomms4594 CrossRefPubMed

24.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 CrossRefPubMedPubMedCentral

25.

Diao B, Wang C, Tan Y et al (2020) Reduction and functional exhaustion of T cells in patientswith coronavirus disease 2019 (COVID-19). MedRxiv 2020.02.18.20024364

26.

Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R (2020) COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev 19:102523. https://doi.org/10.1016/j.autrev.2020.102523 CrossRefPubMedPubMedCentral

27.

Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population based study. Arthritis Rheum 46:2287–2293CrossRefPubMed

28.

Listing J, Gerhold K, Zink A (2012) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 52:53–61CrossRef

29.

Turesson C (2016) Comorbidity in rheumatoid arthritis. Swiss Med Wkly 146:1486

30.

Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387–393PubMed

31.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-217424

32.

Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jin N, Jiang C (2013) Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23(2):300–302. https://doi.org/10.1038/cr.2012.165 CrossRefPubMed

33.

Delogu I, de Lamballerie X (2011) Chikungunya disease and chloroquine treatment. J Med Virol 83(6):1058–1059. https://doi.org/10.1002/jmv.22019 CrossRefPubMedPubMedCentral

34.

Li C, Zhu X, Ji X, Quanquin N, Deng YQ, Tian M, Aliyari R, Zuo X, Yuan L, Afridi SK, Li XF, Jung JU, Nielsen-Saines K, Qin FXF, Qin CF, Xu Z, Cheng G (2017) Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 24:189–194. https://doi.org/10.1016/j.ebiom.2017.09.034 CrossRefPubMedPubMedCentral

35.

Dowall SD, Bosworth A, Watson R, Bewley K, Taylor I, Rayner E, Hunter L, Pearson G, Easterbrook L, Pitman J, Hewson R, Carroll MW (2015) Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J Gen Virol 96(12):3484–3492. https://doi.org/10.1099/jgv.0.000309 CrossRefPubMedPubMedCentral

36.

Vincent MJ, Bergeron E, Benjannet S et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69CrossRefPubMedPubMedCentral

37.

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. https://doi.org/10.1016/j.jcrc.2020.03.005

38.

Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antivir Res 177:104762. https://doi.org/10.1016/j.antiviral.2020.104762 CrossRefPubMed

39.

Gao J, Tian Z, Yang X (2020) Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72–73. https://doi.org/10.5582/bst.2020.01047 CrossRefPubMed

40.

Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia] (2020). Zhonghua Jie He He Hu Xi Za Zhi 43(0):E019. doi: https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0019

41.

Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa237

42.

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:16. https://doi.org/10.1038/s41421-020-0156-0 eCollection 2020CrossRefPubMedPubMedCentral

43.

Zhou D, Dai SM, Tong Q (2020) COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. https://doi.org/10.1093/jac/dkaa114

44.

Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

45.

Ouédraogo DD, Tiendrébéogo-Zabsonré W J, Nikiema R et al (2015) Ophthalmologic assessment of patients on hydroxichloroquine followed for systemic disease. [communication] 6th congress of the Ivorian Rheumatology Society (SOCIRh) 2015.Grand-Bassam. Ivory Coast

46.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061. https://doi.org/10.1001/jama.2020.1585 CrossRefPubMedPubMedCentral

47.

Russell CD, Millar JE, Baillie JK (2020) Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395(10223):473–475. https://doi.org/10.1016/S0140-6736(20)30317-2 CrossRefPubMedPubMedCentral

48.

Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X, Liu Q (2020) Clinical features and short-term outcomes of 102 patients with Corona virus disease 2019 in Wuhan, China. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa243

49.

Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG (2020) Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J 133:1025–1031. https://doi.org/10.1097/CM9.0000000000000744 CrossRefPubMedPubMedCentral

50.

Zheng C, Wang J, Guo H et al (2020) Anhui Medical team members of National aid to prevent and treat novel coronavirus pneumonia in Wuhan. Risk-adapted treatment strategy for COVID-19 patients. Int J Infect Dis. https://doi.org/10.1016/j.ijid.2020.03.047

51.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. https://doi.org/10.1002/jmv.25801

52.

Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, Gargalianos P, Giamarellou H, Gogos C, Daikos G, Lazanas M, Lagiou P, Saroglou G, Sipsas N, Tsiodras S, Chatzigeorgiou D, Moussas N, Kotanidou A, Koulouris N, Oikonomou E, Kaoukis A, Kossyvakis C, Raisakis K, Fountoulaki K, Comis M, Tsiachris D, Sarri E, Theodorakis A, Martinez-Dolz L, Sanz-Sánchez J, Reimers B, Stefanini GG, Cleman M, Filippou D, Olympios CD, Pyrgakis VN, Goudevenos J, Hahalis G, Kolettis TM, Iliodromitis E, Tousoulis D, Stefanadis C (2020) The GReek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design. Hellenic J Cardiol. https://doi.org/10.1016/j.hjc.2020.03.002

53.

Wang W, Ye L, Ye L, Li B, Gao B, Zeng Y, Kong L, Fang X, Zheng H, Wu Z, She Y (2007) Up-regulation of IL-6 and TNF-alpha induced by SARS-coronavirus spike protein in murine macrophages via NF-kappaB pathway. Virus Res 128(1–2):1–8CrossRefPubMedPubMedCentral

Titel: COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments
verfasst von: Dieu-Donné Ouédraogo
Wendlassida Joelle Stéphanie Tiendrébéogo
Fulgence Kaboré
Honoré Ntsiba
Publikationsdatum: 29.05.2020
Verlag: Springer London
Schlagwort: COVID-19
Erschienen in: Clinical Rheumatology / Ausgabe 7/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05189-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients

Are patients with rheumatologic diseases on chronic immunosuppressive therapy at lower risk of developing severe symptoms when infected with COVID-19?

Diagnosing relapsing polychondritis remains a common challenge: experience from a Chinese retrospective cohort

YouTube as a source of information on COVID-19 and rheumatic disease link

COVID-19 with rheumatic diseases: a report of 5 cases

Colchicine may not be effective in COVID-19 infection; it may even be harmful?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin